– Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019 – Phase 2 dose selection and expansion into Phase 2...
PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly...
– The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints(1) – UCB plans to submit applications to regulatory...
Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment 2019 Q3 Interim Report Copenhagen, November 14, 2019 – Zealand...
– Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease — — Company remains well funded with $117.3 million in...
Email
Text